Transenterix Inc (NASDAQ:TRXC) has been assigned an average broker rating score of 2.00 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold rating and two have assigned a strong buy rating to the company.

Brokerages have set a 1-year consensus price objective of $2.48 for the company and are predicting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also assigned Transenterix an industry rank of 113 out of 265 based on the ratings given to its competitors.

TRXC has been the topic of several analyst reports. Zacks Investment Research raised shares of Transenterix from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research report on Wednesday, May 10th. B. Riley lowered shares of Transenterix to a “neutral” rating and set a $0.70 price target on the stock. in a research report on Tuesday, May 16th.

Shares of Transenterix (NASDAQ:TRXC) traded up 12.6334% on Friday, hitting $0.7284. The stock had a trading volume of 1,389,922 shares. The stock’s market cap is $96.43 million. Transenterix has a 12 month low of $0.45 and a 12 month high of $2.33. The stock has a 50 day moving average of $0.68 and a 200-day moving average of $0.95.

In other news, Director Richard C. Pfenniger, Jr. purchased 100,000 shares of Transenterix stock in a transaction dated Tuesday, May 16th. The shares were purchased at an average price of $0.54 per share, with a total value of $54,000.00. Following the transaction, the director now owns 148,000 shares in the company, valued at $79,920. The purchase was disclosed in a document filed with the SEC, which is available through this link.

A hedge fund recently bought a new stake in Transenterix stock. LMR Partners LLP bought a new stake in shares of Transenterix Inc (NASDAQ:TRXC) during the second quarter, according to its most recent 13F filing with the SEC. The firm bought 266,053 shares of the company’s stock, valued at approximately $189,000. LMR Partners LLP owned about 0.18% of Transenterix at the end of the most recent quarter.

WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Get a free copy of the Zacks research report on Transenterix (TRXC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with's FREE daily email newsletter.